Zhou Lei, Wang Yan, Song Xin, Du Jia-wen, Pei Fei, Huang Lin-ping, Wang Wen-yue, Liu Zhi-bin, Pan Rui-qin
Department of General Surgery, China-Japan Friendship Hospital, Beijing 100029, China.
Zhonghua Yi Xue Za Zhi. 2005 Nov 16;85(43):3035-8.
To investigate the clinicopathologic features of and appropriate treatment of ductal carcinoma in situ of the breast (DCIS).
The clinical and pathologic data of 41 cases of DCIS, aged 52.7 (30-82), 15 of which were diagnosed as with ductal carcinoma in situ with microinvasion (DCIS-MI) and of which 18 were in the Van Nuys grade I, 13 in the grade II, and 10 in the grade III, were collected and analyzed. Immunohistochemical analysis was performed to examine the expressions of estrogen receptor (ER), progesterone receptor (PR), proliferating cell nuclear antigen (PCNA), P53 and C-erbB-2.
Microinvasion was correlated with the histologic categories (chi(2) = 4.60, P < 0.05) and tumor size (chi(2) = 9.78, P < 0.05) significantly. The expression rates of ER, PR, PCNA, P53, and C-erbB-2 were 68.3%, 65.9%, 63.4%, 26.8%, and 46.3%, respectively. There was no significant difference in the expression of the biologic markers between the patients with DCIS and those with DCIS-MI. The expression levels of ER, P53, and C-erbB-2 were correlated with the histologic categories significantly (chi(2) = 11.45, 11.97, 4.38, P < 0.05).
The Van Nuys histologic classification accords with the requirement of clinical treatment and prognosis. The patients with DCIS should undergo individualized treatment.
探讨乳腺导管原位癌(DCIS)的临床病理特征及合适的治疗方法。
收集并分析41例DCIS患者的临床和病理资料,患者年龄52.7岁(30 - 82岁),其中15例诊断为伴有微浸润的导管原位癌(DCIS - MI),18例为Van Nuys I级,13例为II级,10例为III级。进行免疫组织化学分析以检测雌激素受体(ER)、孕激素受体(PR)、增殖细胞核抗原(PCNA)、P53和C - erbB - 2的表达。
微浸润与组织学类型(χ² = 4.60,P < 0.05)和肿瘤大小(χ² = 9.78,P < 0.05)显著相关。ER、PR、PCNA、P53和C - erbB - 2的表达率分别为68.3%、65.9%、63.4%、26.8%和46.3%。DCIS患者和DCIS - MI患者之间生物学标志物的表达无显著差异。ER、P53和C - erbB - 2的表达水平与组织学类型显著相关(χ² = 11.45、11.97、4.38,P < 0.05)。
Van Nuys组织学分类符合临床治疗和预后的要求。DCIS患者应接受个体化治疗。